Lilly's targeted RET drug shrinks tumors in lung cancer trial
September 09, 2019 at 03:20 AM EDT
Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.
